Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Muscle-invasive Bladder Cancer Clear all
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Locally Advanced Bladder Cancer

NCT00526656
View directory record Official record
Conditions
Bladder Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 23, 2026, 3:27 AM EDT
Recruiting Phase 2 Interventional

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

NCT03945162
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Interventions
Ruvidar® (TLD-1433) bladder infusion and PDT
Combination Product
Lead sponsor
Theralase® Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 23, 2026, 3:27 AM EDT
Completed Phase 1 Interventional

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

NCT05085990
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
TARA-002
Biological
Lead sponsor
Protara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Jacksonville, Florida • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 23, 2026, 3:27 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

NCT01200992
View directory record Official record
Conditions
Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
Interventions
EN3348, Mitomycin C
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 23, 2026, 3:27 AM EDT
Completed Early Phase 1 Interventional

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

NCT03473730
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC V8
Interventions
Biopsy, Daratumumab, Laboratory Biomarker Analysis, Metastasectomy, Nephrectomy
Procedure · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 23, 2026, 3:27 AM EDT
Completed No phase listed Observational

Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer

NCT02969109
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
Not listed
Lead sponsor
Genomic Health®, Inc.
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 23, 2026, 3:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

NCT07579195
View directory record Official record
Conditions
Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions
Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent, Radical Cystectomy, Pelvic Lymphadenectomy, Stereotactic Body Radiation Therapy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Transurethral Resection of Bladder Tumor, Cystoscopy, Biospecimen Collection, Questionnaire Administration
Radiation · Drug · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 23, 2026, 3:27 AM EDT
Terminated Phase 2 Interventional Results available

Enzalutamide for Bladder Cancer Chemoprevention

NCT02605863
View directory record Official record
Conditions
Bladder Cancer
Interventions
Enzalutamide
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 23, 2026, 3:27 AM EDT
Terminated Phase 2 Interventional Results available

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

NCT01916109
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine, Carboplatin, Panitumumab, radical cystectomy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Sep 23, 2026, 3:27 AM EDT
Terminated Phase 2 Interventional Results available

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT03397394
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma, Ureter Carcinoma, Urinary Bladder Carcinoma, Urethra Carcinoma, Muscle Invasive Bladder Cancer
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 23, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

NCT02015104
View directory record Official record
Conditions
Bladder Cancer
Interventions
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)), PANVAC
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 23, 2026, 3:27 AM EDT
Recruiting Phase 2 Interventional

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

NCT06809140
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Enfortumab vedotin, Pembrolizumab
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Duarte, California • Indianapolis, Indiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 23, 2026, 3:27 AM EDT
Recruiting No phase listed Observational

Predicting BCG Response

NCT04564781
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 23, 2026, 3:27 AM EDT
Recruiting Phase 2 Interventional

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

NCT07061964
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Transurethral Resection of Bladder Tumor
Procedure · Biological · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
165
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 130 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 3:27 AM EDT
Completed Not applicable Interventional Results available

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT02657486
View directory record Official record
Conditions
Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma
Interventions
BGJ398
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 23, 2026, 3:27 AM EDT
Completed No phase listed Observational

Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging

NCT02203136
View directory record Official record
Conditions
Bladder Cancer
Interventions
Tissue Biopsy, Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 23, 2026, 3:27 AM EDT
Recruiting No phase listed Observational

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05825950
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 23, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

NCT02690558
View directory record Official record
Conditions
Bladder Cancer
Interventions
pembrolizumab, gemcitabine and cisplatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 23, 2026, 3:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND)
Biological · Other · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 23, 2026, 3:27 AM EDT
Recruiting Phase 2 Interventional

Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy

NCT06290687
View directory record Official record
Conditions
Malignant Neoplasm of Bladder, Muscle Invasive Bladder Carcinoma
Interventions
Neoadjuvant Chemotherapy, Partial cystectomy with Extended pelvic lymph node dissection, Adjuvant systemic therapy
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 23, 2026, 3:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

NCT02009332
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
ABI-009, Gemcitabine
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 23, 2026, 3:27 AM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

NCT01438112
View directory record Official record
Conditions
Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ, Carcinoma in Situ Concurrent With Papillary Tumors
Interventions
CG0070 Adenovirus Vector, Control Arm: Quadruple Choice
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 23, 2026, 3:27 AM EDT
Terminated Not applicable Interventional Results available

Radiogenomics of Muscle Invasive Bladder Cancer

NCT04806334
View directory record Official record
Conditions
Bladder Cancer Stage II
Interventions
MRI imaging of the pelvis/bladder, genomic analysis of tumor
Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 23, 2026, 3:27 AM EDT
Recruiting Phase 1 Interventional

A Phase I Intravesical PPM Therapy for NMIBC

NCT05519241
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer
Interventions
PLZ4-coated paclitaxel-loaded micelles (PPM)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 23, 2026, 3:27 AM EDT